About Diasure Bio
Diasure Bio is a company based in Seoul (South Korea) founded in 2022. Diasure Bio has raised $71.47 thousand across 1 funding round from investors including InfoBank. Diasure Bio offers products and services including Electrochemical BioSensor and 3D Printing Technology. Diasure Bio operates in a competitive market with competitors including Access Bio, SD Biosensor, Lumos Diagnostics, Fluxergy and Module Innovations, among others.
- Headquarter Seoul, South Korea
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
- Legal Name (주)다이아슈어바이오
- Jurisdiction Na, Maharashtra, India
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$71.47 K (USD)
in 1 rounds
-
Latest Funding Round
$71.47 K (USD), Seed
Nov 27, 2024
- Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Diasure Bio
Diasure Bio offers a comprehensive portfolio of products and services, including Electrochemical BioSensor and 3D Printing Technology.
Device for detecting biological signals in early disease diagnosis.
System for creating medical prototypes using advanced printing methods.
Funding Insights of Diasure Bio
Diasure Bio has successfully raised a total of $71.47K through 1 strategic funding round. The most recent funding activity was a Seed round of $71.47 thousand completed in November 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Seed — $71,475
-
First Round
First Round
(27 Nov 2024)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2024 | Amount | Seed - Diasure Bio | Valuation |
investors |
Investors in Diasure Bio
Diasure Bio has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include InfoBank.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
IT service suite solutions are provided for various business needs.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Diasure Bio
Financial Statements - Diasure Bio
Diasure Bio Comparisons
Competitors of Diasure Bio
Diasure Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Access Bio, SD Biosensor, Lumos Diagnostics, Fluxergy and Module Innovations, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
In vitro rapid diagnostic tests, biosensor, and molecular diagnostic products for diagnosis of infectious diseases.
|
|
| domain | founded_year | HQ Location |
Biosensors for point-of-care diagnostics are developed by SD Biosensor.
|
|
| domain | founded_year | HQ Location |
Diversified diagnostic assays and readers are developed for point-of-care use.
|
|
| domain | founded_year | HQ Location |
Provides diagnostic devices and software for clinical and veterinary point-of-care testing.
|
|
| domain | founded_year | HQ Location |
Diagnostics strip for bacterial detection
|
|
| domain | founded_year | HQ Location |
Point-of-care diagnostic products for diabetes and tuberculosis are provided.
|
Latest news on Diasure Bio
Frequently Asked Questions about Diasure Bio
Diasure Bio was founded in 2022 and raised its 1st funding round 2 years after it was founded.
Diasure Bio is headquartered in Seoul, South Korea.
Seunghwa Lee is the current CEO of Diasure Bio.
Diasure Bio is a funded company, having raised a total of $71.47K across 1 funding round to date. The company's 1st funding round was a Seed of $71.47K, raised on Nov 27, 2024.
Diasure Bio was founded in 2022 and is based in Seoul, South Korea. Operations focus on the diagnostics sector, where point-of-care testing platforms are provided. Analysis methods and products for diagnosing infectious and genetic diseases are developed using 3D printing technology. The company targets rapid antigen testing solutions to support medical diagnostics in various settings.
Diasure Bio's top competitors include Access Bio, SD Biosensor and Lumos Diagnostics.
Diasure Bio offers Electrochemical BioSensor and 3D Printing Technology.
Diasure Bio has 1 investor. Key investors include InfoBank.